Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corp (NASDAQ: SWKH) - a leader in specialized healthcare finance - provides investors and industry stakeholders with critical updates through this centralized news hub. Track all official announcements, strategic developments, and financial disclosures from the company pioneering non-dilutive funding solutions for life science innovators.
This resource delivers verified SWKH news including earnings reports, royalty financing agreements, partnership announcements, and regulatory filings. Investors gain timely access to:
- Quarterly financial performance updates
- Strategic acquisitions and asset purchases
- Enteris BioPharma development milestones
- Portfolio company progress reports
Bookmark this page for direct access to SWK Holdings' latest press releases and market-moving developments. Our curated news collection eliminates fragmented research, providing a reliable single source for monitoring the company's healthcare finance activities and pharmaceutical sector impact.
SWK Holdings (Nasdaq: SWKH) has appointed Adam C. Rice, CPA, as Chief Financial Officer and promoted Courtney Baker, CPA, to Controller. Rice has over 18 years of experience in finance and accounting, previously serving as CFO of Park Cities Asset Management. His background includes roles in financial operations management, corporate financial planning, and strategic planning. Baker, who joined SWK Holdings in July 2023, has expertise in revenue recognition, SEC reporting, and M&A activity. Both executives are CPAs registered in Texas, strengthening SWK's leadership team in finance and accounting.
SWK Holdings (NASDAQ: SWKH) announced its financial results for Q1 2024. The company reported a GAAP net income of $0.9 million, down from $4.6 million in Q1 2023. Adjusted non-GAAP net income for the finance receivables segment was $2.7 million, compared to $7.3 million in the same quarter last year.
As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase year-over-year, with an effective yield of 14.2%. Despite a $6.0 million impairment to its loan book, the company saw a 23.7% revenue increase in its finance segment to $11.5 million.
The book value per share stood at $22.46, while the non-GAAP tangible financing book value per share was $19.69. During the quarter, SWK repurchased 58,298 shares of common stock for approximately $1 million.
SWK's Enteris division signed an Option and Asset Purchase Agreement and received a low-single-digit million-dollar option fee in April 2024. The company remains focused on high-margin, strategic opportunities in the life sciences finance market.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
